Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia ...

Eli Lilly has agreed to acquire Kelonia Therapeutics in a deal valued at up to $7bn, as the company looks to expand its ...

The Haelo Phase 3 trial marks the first late-stage test of an in-vivo CRISPR gene-editing treatment. ・Earlier mid-stage studies showed a 96% reduction in monthly attack rates, with 97% of patients ...

CREATE Medicines, Inc., ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune cell programming, today ...

As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial ...

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

Researchers are advancing in vivo CAR-T cell engineering, which generates therapeutic immune cells directly inside patients, bypassing complex lab manufacturing. This approach could broaden access, ...

Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved ...

A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...

Eli Lilly has agreed to acquire Kelonia Therapeutics for up to $7 billion, in a deal that would bolster the buyer’s oncology ...

Intellia Therapeutics is pioneering in vivo CRISPR gene editing, aiming for groundbreaking therapies, with NTLA-2001 showing promising results in ATTR amyloidosis, potentially achieving blockbuster ...

In April 2026, Regeneron Pharmaceuticals received FDA accelerated approval for Otarmeni, the first in vivo gene therapy for ...